NASDAQ : VNDA
Vanda Pharmaceuticals Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.815 USD (Oct 30, 2026, 2:06 PM EDT) · Market cap 230.69M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 227.06M |
| Enterprise Value | 108.54M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 60.47M |
| Shares Outstanding | 60.47M |
| Shares Change (YoY) | +1.85% |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | 4.20% |
| Owned by Institutions (%) | 69.64% |
| Float | 46.78M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.00 |
| Forward PS | 0.75 |
| PB Ratio | 1.15 |
| P/TBV Ratio | 2.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.54 |
| Quick Ratio | 1.30 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -82.55% |
| Return on Assets (ROA) | -22.61% |
| Return on Invested Capital (ROIC) | -230.56% |
| Return on Capital Employed (ROCE) | -78.25% |
| Weighted Average Cost of Capital (WACC) | 7.33% |
| Revenue Per Employee | $430,165 |
| Profits Per Employee | -$515,627 |
| Employee Count | 533 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 8.24 |
Taxes
| Measure | Value |
|---|
| Income Tax | 103.63M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -13.45% |
| 50-Day Moving Average | 4.76 |
| 200-Day Moving Average | 6.20 |
| Relative Strength Index (RSI) | 26.12 |
| Average Volume (20 Days) | 1,100,988 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.31M |
| Short Previous Month | 7.83M |
| Short % of Shares Out | 13.74% |
| Short % of Float | 17.76% |
| Short Ratio (days to cover) | 7.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 229.28M |
| Gross Profit | 214.57M |
| Operating Income | -177.91M |
| Pretax Income | -171.20M |
| Net Income | -274.83M |
| EBITDA | -169.11M |
| EBIT | -177.91M |
| Loss Per Share | -$4.59 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 140.49M |
| Total Debt | 21.97M |
| Net Cash | 118.52M |
| Net Cash Per Share | $1.96 |
| Equity (Book Value) | 199.86M |
| Book Value Per Share | 3.31 |
| Working Capital | 83.49M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -139.14M |
| Capital Expenditures | -824,000 |
| Depreciation & Amortization | 8.80M |
| Net Borrowing | -3.15M |
| Free Cash Flow | -139.96M |
| FCF Per Share | -$2.31 |
Margins
| Measure | Value |
|---|
| Gross Margin | 93.59% |
| Operating Margin | -77.59% |
| Pretax Margin | -74.67% |
| Profit Margin | -119.87% |
| EBITDA Margin | -73.76% |
| EBIT Margin | -77.59% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.85% |
| Shareholder Yield | -1.85% |
| Earnings Yield | -122.36% |
| FCF Yield | -61.07% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $11.50 |
| Price Target Difference | 206.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 18.87% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.38 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |